

# EXHIBIT 2



National  
Library  
of Medicine

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
<input type="text" value="Search"/> <b>PubMed</b>				<input type="button" value="for"/>	<input type="button" value="Limits"/>	<input type="button" value="Preview/Index"/>	<input type="button" value="History"/>	<input type="button" value="Clipboard"/>	<input type="button" value="Details"/>
<input type="button" value="Go"/>				<input type="button" value="Clear"/>					

[About Entrez](#)

Display  Show:   Send to

[Text Version](#)

1: *J Clin Immunol*. 1996 Sep;16(5):266-71. [Related Articles, Links](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

[Related Resources](#)

[Order Documents](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

### Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy.

**Moss RB, Ferre F, Levine A, Turner J, Jensen FC, Daigle AE, Richieri SP, Truckenbrod A, Trauger RJ, Carlo DJ, Salk J.**

Immune Response Corporation, Carlsbad, California 92008, USA.

Two trials of subjects inoculated with the inactivated, gp120-depleted HIV-1 Immunogen are reported. In one study, in which 19 subjects received ZDV and 8 subjects received ddl, treatment with the HIV-1 Immunogen did not affect the pharmacokinetic parameters of the antiviral drugs. In another study, 65 subjects who were previously immunized with the HIV-1 Immunogen over a mean period of 4.0 years (range, 1.2-5.4 years) received inoculations at 0 and 6 months. At some point during this 48-week study, 72% of the subjects (47/65) were receiving antiviral drug therapy. The HIV-1 DNA load in CD4 cells and CD4 percentage were found to be stable over the 48-week period. Delayed-type hypersensitivity to HIV-1 antigens increased after two inoculations with the HIV-1 Immunogen. In these two trials, no serious treatment-related adverse events were documented in the subjects. The two studies presented herein are the first to suggest that an immune-based therapy such as the HIV-1 Immunogen can be combined safely with antiviral drugs, supporting further study to evaluate the clinical utility of this approach.

#### Publication Types:

- Clinical Trial

PMID: 8886995 [PubMed - indexed for MEDLINE]

Display  Show:   Send to

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement | Freedom of Information Act | Disclaimer](#)

Jun 7 2004 18:11:57